Inoviv Announces FibroKey™: Advancing Non-Invasive Biomarker Monitoring for Fibrosis Research
October 1, 2024 –
London, UK – Inoviv (the “Company”) has announced the launch of FibroKey™, a cutting-edge, mass spectrometry-based assay designed to monitor fibrosis-related protein biomarkers with high precision. FibroKey™ is a quantitative multiplex assay developed to provide researchers and clinicians with non-invasive insights into the progression of chronic kidney disease (CKD) and other fibrotic conditions. By enabling detailed and sensitive analysis of key biomarkers, FibroKey™ helps to improve the understanding of fibrosis mechanisms and accelerate the development of new therapeutic interventions.
Comprehensive Biomarker Panel
FibroKey™ offers an extensive panel of over 35 fibrosis-related biomarkers developed using the InoKey workflow, allowing researchers to capture a complete view of extracellular matrix (ECM) remodeling and inflammatory processes. This diverse panel includes critical biomarkers such as ANXA1, associated with anti-inflammatory responses; CD44, known for its role in cell communication and ECM interaction; and MMP7, which is vital for ECM degradation. The broad biomarker coverage provided by FibroKey™ enables the precise identification of fibrosis at various stages, offering invaluable insights into disease progression and therapeutic efficacy. Researchers and clinicians can tailor their approach to specific disease states, ensuring more targeted treatment strategies.
A Non-Invasive Solution for CKD Research
One of the key features of FibroKey™ is its ability to monitor fibrosis through urine samples, providing an alternative to traditional invasive procedures. This innovative approach significantly reduces patient discomfort while providing robust, reproducible data that can be used to track disease progression. The convenience and accuracy of urine-based assays make FibroKey™ an ideal solution for longitudinal studies and patient monitoring, enabling researchers to observe how fibrosis develops over time or in response to treatment. As the demand for less invasive tools grows, FibroKey™ is positioned to meet the needs of clinical research and population screening in real-world settings.
Powered by the InoKey™ Workflow
FibroKey™ is seamlessly integrated into Inoviv’s proprietary InoKey™ workflow, which provides a comprehensive framework for assay development, validation, and data analysis. InoKey™ ensures that each step in the development of FibroKey™ has been rigorously tested, from discovery to final assay. By combining exploratory proteomics with advanced targeted assays, InoKey™ supports high-throughput screening and robust validation of biomarkers. Researchers using FibroKey™ benefit from the precision of mass spectrometry combined with the reliability of the InoKey™ workflow, facilitating the seamless transition from early-stage discovery to clinical application.
Applications Across Disease Areas
Though initially developed for chronic kidney disease (CKD), FibroKey™ is highly adaptable and can be applied to research in other fibrotic diseases, such as liver fibrosis and pulmonary fibrosis. Its flexibility makes it a valuable asset for pharmaceutical companies, contract research organizations (CROs), and academic institutions aiming to advance fibrosis research. The platform has the potential to support multiple sample types beyond urine —including plasma and tissue—making FibroKey™ suitable for a range of disease models, enhancing its utility in preclinical and clinical studies.
Ready for Clinical Proteomics
FibroKey™ is fully validated for the evaluation of candidate therapeutics and is adaptable for use in clinical trials and drug development programs. The assay supports extended validation for exploratory endpoints and secondary endpoints, making it an essential tool for assessing therapeutic efficacy and disease progression. By delivering accurate, reliable data, FibroKey™ helps researchers to make informed decisions about the patient response, furthering the development of precision medicine approaches in fibrosis management. In addition, the platform can be easily adapted for use in other matrices, such as plasma or serum, allowing for broader application in fibrosis research.
Ernestas Sirka, Chief Scientific Officer:
“FibroKey™ represents a significant advancement in fibrosis research by offering a comprehensive, non-invasive approach to monitoring key biomarkers. The ability to track disease progression through urine samples provides an unprecedented level of accessibility and precision for both researchers and clinicians. We are excited about this platform’s potential for improving therapeutic outcomes in chronic kidney disease and beyond.”
To learn more about FibroKey™ and how it can support your fibrosis research, visit https://inoviv.com/fibrokey/
For research use only. Not for use in diagnostic procedures. Inoviv makes every effort to include accurate and up-to-date information within this publication; however, it is possible that omissions or errors might have occurred. Inoviv cannot therefore, make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided in this publication. Changes in this publication can be made at any time without notice. For technical details and detailed procedures of the specifications provided in this document please contact your Inoviv representative. This brochure may contain reference to applications and products which are not available in all markets. Please check with your local sales representative. Inoviv is a registered trademark of EM Scientific Limited. ©2024 EM Scientific Limited all rights reserved. For disclaimer and trademarks please visit www.inoviv.com
